Last reviewed · How we verify
ATI-50002
At a glance
| Generic name | ATI-50002 |
|---|---|
| Sponsor | Aclaris Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution (PHASE2)
- A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo (PHASE2)
- Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT) (PHASE2)
- A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata (PHASE2)
- Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ATI-50002 CI brief — competitive landscape report
- ATI-50002 updates RSS · CI watch RSS
- Aclaris Therapeutics, Inc. portfolio CI